What is Tirzepatide? A Researcher's Guide to the GLP-1/GIP Dual Agonist

Tirzepatide is a synthetic dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). It represents a significant advancement over earlier GLP-1 mono-agonists, offering a complementary receptor profile that has driven substantial research interest in metabolic disease models.

This guide covers what Tirzepatide is, how it works mechanistically, and why it occupies a distinct position in the incretin research landscape.

What is Tirzepatide?

Tirzepatide is a 39-amino acid synthetic peptide engineered as a single molecule with dual agonist activity. It was developed to combine the well-characterised effects of GLP-1 receptor agonism with the additional metabolic benefits of GIP receptor engagement — a combination not achievable with earlier mono-agonist compounds.

Its two receptor targets are:

  • GLP-1 receptor (GLP-1R) — involved in insulin secretion, appetite suppression, and gastric emptying
  • GIP receptor (GIPR) — involved in insulin and glucagon regulation, and adipose tissue metabolism

Mechanism of Action

By engaging both GLP-1R and GIPR simultaneously, Tirzepatide is studied for its ability to produce additive and potentially synergistic effects on insulin secretion and metabolic regulation. The GIP receptor component is of particular research interest — GIPR agonism has been shown to enhance the insulinotropic effects of GLP-1R activation while also influencing adipose tissue directly, independent of insulin.

This dual-receptor profile makes Tirzepatide a valuable tool for researchers investigating incretin biology, insulin sensitivity, and adipose tissue metabolism.

Why Tirzepatide is of Research Interest

Phase 3 clinical data (SURPASS programme) demonstrated substantial effects on glycaemic control and body weight reduction, with results exceeding those seen with GLP-1 mono-agonists in head-to-head comparisons. This has driven significant academic interest in the dual-agonist mechanism.

Key areas of ongoing research include:

  • Type 2 diabetes and insulin resistance models
  • Obesity and adipose tissue metabolism
  • Non-alcoholic fatty liver disease (NAFLD/NASH)
  • Cardiovascular risk factor modulation
  • Comparative incretin pharmacology studies

Tirzepatide vs. Semaglutide vs. Retatrutide

Understanding where Tirzepatide sits relative to other compounds in the GLP-1 class is important for research design:

  • Semaglutide — GLP-1 mono-agonist; well-characterised, extensive published data
  • Tirzepatide — GLP-1/GIP dual-agonist; adds GIP receptor engagement for enhanced metabolic effects
  • Retatrutide — GLP-1/GIP/glucagon tri-agonist; further adds glucagon receptor engagement for enhanced energy expenditure research

Each compound offers a distinct receptor profile, making them useful for comparative mechanistic studies across the incretin class.

Sourcing Tirzepatide for Research

Research-grade Tirzepatide should be sourced from suppliers providing batch-specific Certificates of Analysis (CoA) confirming purity (>98%), identity, and potency. Lyophilised formats offer optimal stability for laboratory storage.

At Aura Peptides, our Tirzepatide is supplied as a research-grade lyophilised peptide with full CoA documentation, available as single vials or in 10x bulk packs for high-volume research programmes.

For research purposes only. Not intended for human or veterinary use.

Back to blog